- Home
- MXL vs AUPH Comparison
MXL vs AUPH Comparison
Compare MXL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXL
- AUPH
- Stock Information
- Founded
- MXL 2003
- AUPH 1993
- Country
- MXL United States
- AUPH Canada
- Employees
- MXL N/A
- AUPH N/A
- Industry
- MXL Semiconductors
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- MXL Technology
- AUPH Health Care
- Exchange
- MXL Nasdaq
- AUPH Nasdaq
- Market Cap
- MXL 1.1B
- AUPH 1.1B
- IPO Year
- MXL 2010
- AUPH 1999
- Fundamental
- Price
- MXL $11.65
- AUPH $8.05
- Analyst Decision
- MXL Buy
- AUPH Strong Buy
- Analyst Count
- MXL 7
- AUPH 2
- Target Price
- MXL $25.58
- AUPH $11.50
- AVG Volume (30 Days)
- MXL 1.3M
- AUPH 1.4M
- Earning Date
- MXL 04-23-2025
- AUPH 05-01-2025
- Dividend Yield
- MXL N/A
- AUPH N/A
- EPS Growth
- MXL N/A
- AUPH N/A
- EPS
- MXL N/A
- AUPH 0.04
- Revenue
- MXL $360,528,000.00
- AUPH $235,133,000.00
- Revenue This Year
- MXL $24.50
- AUPH $11.86
- Revenue Next Year
- MXL $19.87
- AUPH $24.96
- P/E Ratio
- MXL N/A
- AUPH $201.00
- Revenue Growth
- MXL N/A
- AUPH 33.97
- 52 Week Low
- MXL $10.21
- AUPH $4.71
- 52 Week High
- MXL $26.59
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- MXL 38.26
- AUPH 44.83
- Support Level
- MXL $10.21
- AUPH $7.93
- Resistance Level
- MXL $13.50
- AUPH $8.73
- Average True Range (ATR)
- MXL 0.64
- AUPH 0.23
- MACD
- MXL 0.03
- AUPH -0.04
- Stochastic Oscillator
- MXL 43.77
- AUPH 15.00
About MXL MaxLinear Inc.
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.